Life science startups, whether you are in biotech, medtech, digital health, or running a CRO, face a core question: should you focus on marketing or business development (BD)?
There is no one answer. The balance depends on what you sell, who buys it, and your growth stage. Marketing builds awareness, educates buyers, and generates leads. Business development in life sciences closes deals, forms strategic partnerships, and builds one-to-one relationships.
Your business model, sales cycle, and industry norms set the priorities. Let’s break it down.
Marketing vs. BD in Life Science Startups
Early-stage companies need both, but the emphasis shifts by sector. Marketing drives education and demand. BD secures pilots, partnerships, and revenue. The mix depends on norms, sales cycles, and stage. Below we cover therapeutics, medical devices, digital health, and service companies, and when each should lean on marketing or BD.
Therapeutics (Biotech and Pharma Startups)
Therapeutics startups operate in a regulated, R&D heavy context with long timelines. Many spend years in preclinical and clinical phases before any product reaches the market. Direct product marketing is usually not possible until approval. Early best practice is to focus on scientific credibility and strategic partnerships.
The sale is not to a consumer. It is to a larger pharma company or investors. Licensing deals and alliances are common and slow. They can take months of diligence and negotiation. For firms that do go to market alone, adoption requires physicians, patients, and payers. That is hard and expensive.
Given these norms, BD is usually more critical in early and mid stages. Core BD activities include development partnerships, co-development, and out-licensing. Partnerships bring funding, expertise, and a route to market. Marketing still matters, but in service of credibility. Think conference talks, peer-reviewed data, and targeted networking that raises visibility with scouts and investors. If the startup remains independent into commercialization, traditional marketing becomes a priority later. Even then, it often runs with or through a pharma partner.
Practical focus: prioritize BD over broad marketing in early phases. Use marketing to support BD with sharp scientific narratives and investor materials. As you approach Phase II or III, ramp BD for licensing or acquisition. If you become a commercial-stage pharma, shift to heavy marketing and sales execution.
Medical Devices
Device startups are product driven, face moderate regulatory hurdles, and need clinical validation. Development involves prototyping, trials, and clearance or approval. Early entry often uses pilots in hospitals or clinics and endorsements from key opinion leaders.
Sales cycles are long. Eight months is common. A year or more happens. Decisions involve physicians, procurement, budget holders, and sometimes patients. Trust and relationships matter.
Marketing supports the journey. Use conferences, clinical data, and targeted physician education to build credibility and generate inbound interest. It will not close complex hospital deals on its own. BD must convert. That means KOL cultivation, pilots with leading clinics, distribution agreements, and account management.
Practical focus: in early phases, lean on BD to set up clinical partnerships and distribution. Use marketing to amplify evidence and educate stakeholders. Post-approval, ramp marketing to drive demand while BD and sales convert and expand accounts.
Digital Health
Digital health spans software, apps, and tech-enabled services across B2C, B2B, and hybrid models. Development cycles are faster in many cases, but trust and outcomes still decide winners. Buyers want proof and smooth integration.
B2C models: marketing is primary. You win with user acquisition, activation, and retention. Use SEO, content, paid social, communities, and app store optimization. BD helps when it accelerates growth through distribution deals, employer benefits, or device partnerships.
B2B models: BD is primary. Enterprise sales to providers, payers, or employers take 6 to 18 months. Multiple stakeholders weigh in. Marketing supports BD with case studies, ROI proof, and thought leadership. Channel partnerships can be a force multiplier. Buyers have point solution fatigue. Integrate into larger platforms when you can.
Practical focus: choose based on your model. Consumer growth needs marketing first, with selective BD for distribution. Enterprise growth needs BD first, with marketing building trust and filling the pipeline. Best-in-class teams synchronize both.
Service-Based Life Science Companies
CROs, CDMOs, Diagnostics Services
Service firms sell high-value, trust-based work. Reputation and relationships drive growth. Sales cycles can run 6 to 18 months. RFPs and referrals are common. Sponsors prefer providers they trust. Strategic partnerships and preferred-provider lists are rising.
BD is the engine. Senior leaders and BD managers meet prospects, shape solutions, and manage key accounts. Strategic alliances expand capability or reach. Marketing supports credibility with a professional site, case studies, scientific content, webinars, and conference presence. It warms leads and equips BD, but rarely wins complex deals alone.
Practical focus: early firms should concentrate on BD to win anchor clients. Maintain a credible marketing base. As you scale, invest more in SEO, case studies, and content that showcases success. Keep BD at the center for large contracts and key accounts.
Adjusting the Focus by Company Stage
The mix evolves with maturity.
Startup stage: BD often delivers faster value. Secure a pilot, a partnership, or an anchor customer. Marketing focuses on clarity and credibility. Build a clean site, crisp messaging, and milestone news. Validate before you scale.
Scale-up stage: with product-market fit, increase marketing. Build reach and fill the pipeline. BD shifts to larger strategic deals, distribution, and systematic account growth.
A common sequence
- Use BD to win early traction.
- Use marketing to scale awareness and demand.
- Keep BD focused on high-value deals and relationships.
Sector Summary
| Company Type | Marketing Priority | BD Priority | Focus Areas |
|---|---|---|---|
| Therapeutics | ⭐⭐ | ⭐⭐⭐⭐⭐ | BD for licensing and partnerships. Marketing for scientific credibility. |
| Medical Devices | ⭐⭐⭐⭐ | ⭐⭐⭐⭐ | BD for clinical adoption and distribution. Marketing for education and awareness. |
| Digital Health (B2C) | ⭐⭐⭐⭐⭐ | ⭐⭐ | Marketing for user acquisition. BD for growth partners. |
| Digital Health (B2B) | ⭐⭐⭐ | ⭐⭐⭐⭐⭐ | BD for enterprise sales. Marketing for proof and lead gen. |
| CROs, CDMOs, Diagnostics | ⭐⭐⭐ | ⭐⭐⭐⭐⭐ | BD wins contracts. Marketing builds trust and brand. |
Key Takeaways
-
Biotech needs BD first, marketing later. Your sale is a licensing deal, not a consumer product.
-
Medical devices need a combo. BD for early adoption and distribution. Marketing for education.
-
Digital health splits by model. Marketing for B2C, BD for B2B. Synchronize both to scale.
-
Service providers live on BD. Marketing supports credibility and equips the team.
-
Stage matters. Early stage is BD heavy. Scaling means ramping marketing while BD targets larger deals.
The goal is not marketing or BD. It is using both at the right time. Nail the balance and you will grow faster with less wasted effort. For deeper BD strategy in biotech, see our cornerstone on business development in life sciences.
Sources
-
University Lab Partners, Business Development Basics
-
Labiotech.eu, The ABC of Biotech Partnerships
-
V-Bio Ventures, From Lab to Market: The Life Cycle of a Biotech Startup
-
Consonance MedTech Blog, Launching a Medical Device Startup: Key Success Factors
-
Responsify, How to Shorten Your Medical Device Sales Cycle
-
Andreessen Horowitz, Channel Partnerships in Healthcare
-
Reddit r/clinicalresearch, CRO Business Development discussion
-
RxJam, The Role of Sales and Business Development in CDMO Marketing
-
Applied Clinical Trials Online, CRO and Sponsor Strategic Relationships
